Status:

WITHDRAWN

Rejuvenation of Aged Muscle Stem Cells Through Exercise

Lead Sponsor:

Duke University

Collaborating Sponsors:

National Institutes of Health (NIH)

National Institute on Aging (NIA)

Conditions:

Autophagy and Apoptosis in Human Satellite Cells

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

The proposed study will establish a newly-identified signaling pathway regulating both autophagy and apoptosis in human satellite cells. These findings will allow for novel pharmacological targets in ...

Eligibility Criteria

Inclusion

  • Age 21 years or greater.
  • No medication changes within the last 3 months.
  • Not participating in regular physical exercise (more than 60 minutes of moderate intensity or 30 minutes of vigorous intensity exercise per week).
  • Able to decide if you want to take part in the study.

Exclusion

  • Smoker: Tobacco use within the last 12 months.
  • Dieting or intending to diet.
  • Use of potential confounding medications, e.g. using ticlopidine, clopidogrel, dipyridamole, warfarin, heparin, enoxaparin and other blood thinners.
  • Coronary stents or any other medical condition for which aspirin cannot be temporarily withheld.
  • Use of hormone replacement medications.
  • Absolute contra-indications to exercise: Recent (\<6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurysm and acute systemic infection.
  • Relative contra-indications to exercise: Left main coronary stenosis, moderate stenotic valvular heart disease, outflow tract obstruction, high degree AV block, ventricular aneurysm, uncontrolled metabolic disease (e.g. diabetes, thyrotoxicosis, myxedema), uncontrolled pulmonary disease (e.g. severe COPD or pulmonary fibrosis), mental or physical impairment leading to inability to exercise adequately.
  • Have a confounding medical condition that is progressive and unstable such as HIV, Hepatitis C, active cancer, and/or taking medications for those conditions.
  • Unwillingness to be randomized to any one of two intervention groups, submit to skeletal muscle biopsies and all other study testing or continuously participate in a randomly assigned exercise training or program for three months.
  • Orthopedic limitations, musculoskeletal disease and/or injury.
  • Allergic to xylocaine.
  • Unwillingness to exercise at the Duke Center for Living during staff supervised times.

Key Trial Info

Start Date :

January 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 6 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03473288

Start Date

January 1 2021

End Date

June 6 2021

Last Update

June 10 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Duke University Medical Center

Durham, North Carolina, United States, 27710